Vous êtes ici: Startseite Französis... > Services médicaux > Collaborateurs > Kwadwo Antwi

Collaborateurs

PD Dr. med. Kwadwo Antwi

Leiter Nuklearmedizin
Leitender Arzt Nuklearmedizin

Portrait PD Dr. med. Kwadwo Antwi
  • Kudura K, Ritz N, Templeton AJ, Kissling M, Kutzker T, Foerster R, Hoffmann MHK, Antwi K, Kreissl MC: Additional primary tumors detected incidentally on FDG PET/CT at staging in patients with first diagnosis of NSCLC: frequency, impact on patient management and survival. Cancers: 15 (5): 1521.
  • Kudura K, Ritz N, Templeton AJ, Kutzker T, Foerster R, Antwi K, Kreissl MC, Hoffmann MHK: Predictive Value of Total Metabolic Tumor Burden prior to treatment in NSCLC Patients Treated with Immune Checkpoint Inhibition. J Clin Med: 12 (11): 3725.
  • Kudura K, Ritz N, Templeton AJ, Kutzker T, Hoffmann MK, Antwi K, Zwahlen DR, Kreissl MC, Foerster R: Breaking Methodological Boundaries in Outcome Prediction: An Innovative Non-Linear Model Integrating Primary Tumor Features on Baseline FDGPET/CT, Molecular Subtype and Clinical Data for Treatment Benefit Prediction in Women with Newly Diagnosed Breast Cancer. Cancers: 15 (22): 5476.
  • Antwi K, Caobelli F, Kudura K, Buchholz HG, Hoffmann M, Schreckenberger M: Hypermetabolic Ipsilateral Supraclavicular and Axillary Lymphadenopathy: Optimal Time Point for Performing an 18F-FDG PET/CT after COVID-19 Vaccination. Diagnostics (Basel) 12(12): 3073 (2022).
  • Kudura K, Ritz N, Kutzker T, Hoffmann M, Templeton AJ, Foerster R, Kreißl MC, Antwi K: Predictive value of baseline FDG-PET/CT for durable response to immune checkpoint inhibition in NSCLC patients using morphological and metabolic features of primary tumor. Cancers 14(24): 6095 (2022).
  • Hepprich M, Antwi K, Wiesner P, Cavelti-Weder C, Donath M, Christ E, Wild D: Glucagon-Like Peptide-1 Receptor Pet/Ct in Patients with and Without Post Gastric Bypass Hypoglycemia: A Prospective, Matched Case-Control Study. J Gastro intest DigSyst. Vol 12(5) (2022)
  • Antwi, K., Wiesner, P., Merkle, E., Zech, C. J., Boll, D., Wild, D., Christ, E.; Heye, T., Investigating Difficult to Detect Pancreatic Lesions: Characterization of benign Pancreatic Islet Cell Tumors Using Multiparametric Pancreatic 3-T MRI. PLOS ONE (2021 accepted)
  • Wild D, Antwi K, Fani M, Christ ER. Glucagon-like Peptide-1 Receptor as Emerging Target: Will It Make It to the Clinic? J Nucl Med. 2021 44S-50S
  • Antwi K, Hepprich M, Müller NA, Reubi JC, Fani M, Rottenburger C, Nicolas G, Kaul F, Christ ER, Wild D. Pitfalls in the Detection of Insulinomas With Glucagon-Like Peptide-1 Receptor Imaging. Clin Nucl Med. Sep;45(9):e386-e392 (2020).
  • Hepprich M, Antwi K, Waser B, Reubi JC, Wild D, Christ ER. Brunner's Gland Hyperplasia in a Patient after Roux-Y Gastric Bypass: An Important Pitfall in GLP-1 Receptor Imaging. Case Rep Endocrinol. Apr 3;2020:4510910 (2020)
  • Schunemann MJ, Vosbeck J, Antwi K, Bassetti S, Osthoff M. Wither Away: Weight Loss and Persistent Inflammation in a Woman With Whipple Disease. Am J Med.;133(6):e223-e226 (2020). 
  • Christ, E., Antwi, K., Fani, M. & Wild, D. 'Innovative imaging of insulinoma: the end of sampling? A review', Endocr Relat Cancer. Apr;27(4):R79-R92 (2020).
  • Antwi K, Nicolas GP, Wild D, Christ E. Molecular imaging of neuroendocrine tumours. Swiss Med Wkly. Okt 09; (2019).
  • Valente LG, Antwi K, Nicolas GP, Wild D, Christ E. Clinical presentation of 54 patients with endogenous hyperinsulinaemic hypoglycaemia: a neurological chameleon (observational study). Swiss Med Wkly. Nov 18;148:w14682 (2018). 
  • Antwi, K., Nicolas, G., Wild, D. & Christ, E. 'Molecular imaging for neuroendocrine tumours', Swiss Med Wkly, 10;149, w2017 (2019).
  • Antwi, K., Nicolas, G., Fani, M., Christ, E. & Wild, D. 'Volume Replacement Fluid Demarks Benign Insulinoma With 68Ga-DOTA-Exendin-4 PET/CT', Clin Nucl Med, 44(5), e347-e48 (2019). 
  • Antwi K, Nicolas G, Fani M, Heye T, Pattou F, Grossman A, Chanson P, Reubi JC, Perren A, Gloor B, Vogt DR, Wild D, Christ E. 68Ga-Exendin-4 PET/CT Detects Insulinomas in Patients With Endogenous Hyperinsulinemic Hypoglycemia in MEN-1. J Clin Endocrinol Metab;104(12):5843-5852 (2019).
  • Antwi, K., Fani, M., Heye, T., Nicolas, G., Rottenburger, C., Kaul, F., Merkle, E., Zech, C. J., Boll, D., Vogt, D. R., Gloor, B., Christ, E. & Wild, D. 'Comparison of glucagon-like peptide-1 receptor (GLP-1R) PET/CT, SPECT/CT and 3T MRI for the localisation of occult insulinomas: evaluation of diagnostic accuracy in a prospective crossover imaging study', Eur J Nucl Med Mol Imaging, 45(13), 2318-27 (2018).
  • Wenning, A. S., Kirchner, P., Antwi, K., Fani, M., Wild, D., Christ, E. & Gloor, B. 'Preoperative Glucagon-like peptide-1 receptor imaging reduces surgical trauma and pancreatic tissue loss in insulinoma patients: a report of three cases', Patient Saf Surg, 9, 23. (2015)
  • Cuthbertson, D. J., Banks, M., Khoo, B., Antwi, K., Christ, E., Campbell, F., Raraty, M. & Wild, D. 'Application of Ga(68) -DOTA-exendin-4 PET/CT to localize an occult insulinoma', Clin Endocrinol (Oxf), 84(5), 789-91 (2016).
  • Antwi, K., Fani, M., Nicolas, G., Rottenburger, C., Heye, T., Reubi, J. C., Gloor, B., Christ, E. & Wild, D. 'Localization of Hidden Insulinomas with ⁶⁸Ga-DOTA-Exendin-4 PET/CT: A Pilot Study', J Nucl Med, 56(7), 1075-8. (2015)
  • Christ E, Wild D, Antwi K, Waser B, Fani M, Schwanda S, Heye T, Schmid C, Baer HU, Perren A, Reubi JC. Preoperative localization of adult nesidioblastosis using ⁶⁸Ga-DOTA-exendin-4-PET/CT. Endocrine, 50, 821-3 (2015)
  • *M. Miederer, C. Fottner, K. Antwi, M. Weber, M. Schreckenberger (2011) Einsatz der Positronen-Emissions-Tomografie bei ­neuroendokrinen Tumoren. Nuklearmediziner 2011; 34(04): 214-219

 

Coordonnées

Nos heures d'ouverture exécuter du lundi au vendredi 8 heures – 17 heures En dehors des heures de téléphone notre réception est ouverte en permanence.

Réception:

T: 061 685 85 85